GLP-1 weight loss plateaus: what the science says about breaking through
Quick answer
After approximately 38 kilograms of weight loss on tirzepatide, this creator's experience of stalling and then recalibrating her calorie intake reflects a well-documented physiological reality: TDEE decreases substantially with significant weight reduction, and patients who do not update their intake targets will inadvertently eat at or above maintenance. Clinically, TDEE recalculation is a standard recommendation in weight management, but prescribers should also assess adaptive thermogenesis, GLP-1 dose appropriateness, and whether the plateau represents a new physiological equilibrium rather than a tracking error alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @hez.gets.healthy actually say?
The short version: she stalled for roughly eight weeks on Mounjaro, broke through it last week with a pound and a half loss, then dropped three pounds this week. Her practical tip was blunt and specific: "double-check your TDEE" because she was eating "about 400 more calories a day" than her updated bodyweight required after losing six stone. She wrapped it with encouragement to keep going.
This is personal testimony, not a protocol. She is not claiming a medical intervention worked. She is sharing that rechecking her calorie target after significant weight loss appeared to break a plateau. That distinction matters when evaluating what she is actually putting out there.
Does the science back this up?
Yes, and more strongly than most TikTok plateau advice. The core claim, that your calorie needs drop as you lose weight, is one of the most replicated findings in obesity research and the mechanism is well understood.
When body weight falls, total daily energy expenditure (TDEE) falls with it. This happens through two routes. First, a lighter body simply burns fewer calories at rest. Second, there is a phenomenon called adaptive thermogenesis, where the body actively downregulates metabolism beyond what body composition alone would predict. Rosenbaum and Leibel (2010, New England Journal of Medicine) documented this clearly in long-term weight-reduced subjects. More recently, Hall et al. (2022, Obesity) confirmed that people maintaining large weight losses show suppressed energy expenditure relative to never-obese controls at the same weight.
The specific number she cited, around 400 calories, is plausible. A six-stone loss is approximately 38 kilograms. Standard TDEE calculators would reduce estimated maintenance by roughly 300 to 500 calories at that scale of loss, depending on activity level and starting weight. Her figure is not precise medical advice, but it is in the right ballpark.
What did they get wrong (or right)?
She got the core mechanism right. Eating to a stale calorie target after losing six stone is a genuine and common reason plateaus persist, and recalibrating TDEE is a legitimate first-line response. Credit where it is due.
What she did not mention is adaptive thermogenesis, the second driver, which matters. Even after correctly recalculating TDEE using a standard formula, some people will still plateau because their actual metabolic rate sits below what the formula predicts. TDEE calculators use population averages. They do not measure your personal metabolic adaptation. This means recalculating calories is a necessary step, not always a sufficient one.
She also implicitly frames the plateau as entirely within her control through calorie tracking. For GLP-1 users specifically, dose titration, injection timing, and individual receptor response variation all interact with weight trajectory in ways that a calorie check alone does not address. None of this makes her advice wrong. It makes it incomplete.
The encouragement framing, "it'll come, just keep going," is fine for motivation but could give some viewers false reassurance that persistence alone will break any plateau. Sometimes it will not, and a conversation with a prescriber is warranted.
What should you actually know?
If you are on a GLP-1 medication and have stalled, here is what the evidence actually supports as reasonable next steps.
- Recalculate your TDEE using your current bodyweight, not your starting weight. Free tools like the Mifflin-St Jeor equation are reasonably accurate for most people. Her advice here is sound.
- Understand that the formula gives an estimate. If you recalculate and still stall after four to six weeks, your individual metabolic adaptation may be running below the population average.
- Plateaus on GLP-1 medications are documented in the trial data. In the SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, New England Journal of Medicine), weight loss was not linear across the treatment period. Rate of loss naturally slows as you approach a new equilibrium.
- Do not self-adjust your dose based on a plateau. That conversation belongs with your prescriber, who can assess whether titration, adherence, or other clinical factors are relevant.
- Sleep, resistance training, and protein intake all influence whether weight loss comes from fat versus lean mass during a deficit. These are not discussed in the video but are relevant to how plateau management plays out over time.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 weight loss plateaus: what the science says about breaking through, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
After approximately 38 kilograms of weight loss on tirzepatide, this creator's experience of stalling and then recalibrating her calorie intake reflects a well-documented physiological reality: TDEE decreases substantially with significant weight reduction, and patients who do not update their intake targets will inadvertently eat at or above maintenance.
FormBlends verdict
After approximately 38 kilograms of weight loss on tirzepatide, this creator's experience of stalling and then recalibrating her calorie intake reflects a well-documented physiological reality: TDEE decreases substantially with significant weight reduction, and patients who do not update their intake targets will inadvertently eat at or above maintenance. Clinically, TDEE recalculation is a standard recommendation in weight management, but prescribers should also assess adaptive thermogenesis, GLP-1 dose appropriateness, and whether the plateau represents a new physiological equilibrium rather than a tracking error alone.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- After approximately 38 kilograms of weight loss on tirzepatide, this creator's experience of stalling and then recalibrating her calorie intake reflects a well-documented physiological reality: TDEE decreases substantially with significant weight reduction, and patients who do not update their intake targets will inadvertently eat at or above maintenance. Clinically, TDEE recalculation is a standard recommendation in weight management, but prescribers should also assess adaptive thermogenesis, GLP-1 dose appropriateness, and whether the plateau represents a new physiological equilibrium rather than a tracking error alone.
- TDEE decreases by roughly 300 to 500 calories after a 38 kg weight loss, making stale calorie targets a genuine and common plateau driver supported by Hall et al. (2022, Obesity).
- Adaptive thermogenesis means your actual metabolic rate can sit below what TDEE calculators predict after major weight loss, documented in Rosenbaum and Leibel (2010, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- TDEE decreases by roughly 300 to 500 calories after a 38 kg weight loss, making stale calorie targets a genuine and common plateau driver supported by Hall et al. (2022, Obesity).
- Adaptive thermogenesis means your actual metabolic rate can sit below what TDEE calculators predict after major weight loss, documented in Rosenbaum and Leibel (2010, NEJM).
- SURMOUNT-1 trial data (Jastreboff et al., 2022, NEJM) shows tirzepatide-associated weight loss is not linear, and plateau periods are expected within the normal treatment course.
- Recalculating TDEE using current bodyweight via the Mifflin-St Jeor equation is a reasonable first step when plateaued, but it is an estimate, not a personalised metabolic measurement.
- Dose adjustments for GLP-1 medications should never be self-directed based on a plateau. This is a clinical decision requiring prescriber input.
- A plateau lasting more than six to eight weeks on a GLP-1 medication warrants a conversation with your prescriber, not just a calorie audit.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
✨️Heather✨️ First Time Mum 🤍 · TikTok creator
2.0K views on this video
the plateau WILL END 👏 #weightlossjourney #plateau #glp1forweightloss #glp1 #mounjarocommunity #mounjarouk #mounjarojourney
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by ✨️Heather✨️ First Time Mum 🤍, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.